Loading…
MediciNova, Inc. is projected to rise to $1.40 by 2027, a +5% move from its current price of $1.33. MNOV is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.31 | $1.33 | $1.35 | +0.01% |
| May 30 | $1.30 | $1.33 | $1.36 | +0.01% |
| May 31 | $1.29 | $1.33 | $1.37 | +0.02% |
| Jun 1 | $1.28 | $1.33 | $1.38 | +0.02% |
| Jun 2 | $1.28 | $1.33 | $1.38 | +0.03% |
| Jun 3 | $1.27 | $1.33 | $1.39 | +0.03% |
| Jun 4 | $1.27 | $1.33 | $1.39 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.27 | $1.33 | $1.39 | +0.04% |
| Week 2 | $1.25 | $1.33 | $1.42 | +0.08% |
| Week 3 | $1.23 | $1.33 | $1.44 | +0.12% |
| Week 4 | $1.21 | $1.33 | $1.46 | +0.16% |
| Week 5 | $1.20 | $1.33 | $1.48 | +0.20% |
| Week 6 | $1.19 | $1.33 | $1.50 | +0.24% |
| Week 7 | $1.18 | $1.33 | $1.51 | +0.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MediciNova, Inc. is a biopharmaceutical company focused on developing novel and small molecule therapeutics for serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglyceridemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
MediciNova, Inc. (MNOV) is valued at $1.40 per share with a market capitalization of $68.91M and a market rank of 4442. The current price sits near short- and medium-term moving averages, reflecting a tightly tuned price level at $1.41 for both the SMA50 and SMA200.
The stock trades within a 30-day range of $1.25 to $1.57, with a defined support at $1.36 and resistance at $1.47.
Technical sentiment is bullish, and volatility runs at about 30% annualized. These technicals describe a cautious uptrend near a pivotal price zone, suggesting investors are weighing a modest near-term upside against ongoing development-stage risk. The broader forecast projects a multi-year rise from the current level toward higher price points in the years ahead.
A major floor 7.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 10.5% above — a clean break opens room to run.
A major ceiling 41.4% above — clearing it would confirm fresh momentum.
Key MNOV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MNOV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.37 | Sell | $1.36 | Sell |
| MA 10 | $1.38 | Sell | $1.38 | Sell |
| MA 20 | $1.39 | Sell | $1.39 | Sell |
| MA 50 | $1.41 | Sell | $1.41 | Sell |
| MA 100 | $1.47 | Sell | $1.43 | Sell |
| MA 200 | $1.41 | Sell | $1.44 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.36 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -224.68 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -5.00 | Sell |
| Bollinger %B (20,2) | -0.12 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.10 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 33.28 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 1.36 | Sell |
| ADX (14) | 8.13 | Neutral |
| ATR (14) | 0.02 | Info |
Over the next 30 days, the picture is guided by a bullish tilt in sentiment with RSI at 50. The price remains clustered around the $1.41 area, touching the SMA50 and SMA200 at $1.41. Support sits at $1.36, while resistance is seen at $1.47, framing a tight range between $1.25 and $1.57 over the past month.
The near-term setup favors a cautious advance as buyers test the resistance level near $1.47. If the price breaks above that level, the next upside target would be the upper end of the 30-day range at $1.57. If downside pressure intensifies, the $1.36 support provides a reference point for potential retracements toward the lower end of the range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.30 | $1.33 | $1.67 | 0% | Neutral | |
| $1.14 | $1.40 | $1.79 | +5% | Neutral | |
| $1.13 | $1.41 | $1.85 | +6% | Neutral | |
| $1.36 | $1.72 | $2.31 | +30% | Bullish | |
| $1.51 | $1.93 | $2.64 | +45% | Bullish | |
| $1.53 | $1.98 | $2.75 | +49% | Bullish | |
| $1.67 | $2.20 | $3.09 | +65% | Bullish | |
| $1.63 | $2.17 | $3.08 | +63% | Bullish | |
| $1.65 | $2.21 | $3.18 | +66% | Bullish | |
| $1.91 | $2.58 | $3.75 | +94% | Bullish | |
| $2.40 | $3.38 | $5.16 | +154% | Bullish | |
| $4.43 | $6.69 | $10.95 | +403% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.30 | $1.33 | $1.56 | +0.00% |
| June 2026 | $1.15 | $1.35 | $1.60 | +1.18% |
| July 2026 | $1.14 | $1.34 | $1.60 | -0.65% |
| August 2026 | $1.16 | $1.37 | $1.66 | +2.38% |
| September 2026 | $1.18 | $1.40 | $1.70 | +1.93% |
| October 2026 | $1.15 | $1.37 | $1.67 | -2.15% |
| November 2026 | $1.13 | $1.34 | $1.65 | -1.82% |
| December 2026 | $1.13 | $1.35 | $1.67 | +1.00% |
Click any year to see its month-by-month MNOV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MNOV is projected to trade between $1.30 and $1.67, averaging $1.33 — a potential gain of 0% from today's $1.33. A consolidation phase looks the most probable path here.
MediciNova, Inc.'s 2027 outlook centres on $1.40, within a $1.14 to $1.79 range. That is up +5% on the projected 2026 average. That marks a +5% change versus current levels. Price action looks broadly range-bound.
By 2028, MNOV could reach as high as $1.85, with a base case around $1.41 and support toward $1.13 — roughly +6% from $1.33. A consolidation phase looks the most probable path here.
Expect MNOV to range from $1.36 to $2.31 through 2029. The $1.72 average target implies a +30% move from current prices. That is up +22% on the projected 2028 average. Momentum favours further upside here.
The MNOV price prediction for 2030 points to an average of $1.93 (low $1.51, high $2.64) — a potential gain of +45% on today's $1.33. Buyers look set to stay in control over this stretch.
In 2031, MNOV is projected to trade between $1.53 and $2.75, averaging $1.98 — a potential gain of +49% from today's $1.33. That is up +3% on the projected 2030 average. Momentum favours further upside here.
MediciNova, Inc.'s 2032 outlook centres on $2.20, within a $1.67 to $3.09 range. That is up +11% on the projected 2031 average. That marks a +65% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MNOV could reach as high as $3.08, with a base case around $2.17 and support toward $1.63 — roughly +63% from $1.33. Momentum favours further upside here.
Expect MNOV to range from $1.65 to $3.18 through 2034. The $2.21 average target implies a +66% move from current prices. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The MNOV price prediction for 2035 points to an average of $2.58 (low $1.91, high $3.75) — a potential gain of +94% on today's $1.33. Momentum favours further upside here.
In 2040, MNOV is projected to trade between $2.40 and $5.16, averaging $3.38 — a potential gain of +154% from today's $1.33. That is up +31% on the projected 2035 average. Buyers look set to stay in control over this stretch.
MediciNova, Inc.'s 2050 outlook centres on $6.69, within a $4.43 to $10.95 range. That is up +98% on the projected 2040 average. That marks a +403% change versus current levels. Momentum favours further upside here.
Investing $1,000 in MNOV today (≈ 751.879699 MNOV) could be worth
$5,031.46
+$4,031.46 (+403%) by 2050 · US Dollar
Based on the average projected MNOV price of $6.69 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MNOVwould be worth at today's price.
$1,000 invested in MNOV on May 27, 2025 (≈ 699.300725 MNOV) would be worth
$930.07
-$69.93 (-7.0%) today · 0.93× · US Dollar
Based on a MNOV entry price of $1.43 vs. today's $1.33.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.39 | $956.83 | -4.3% |
| 1 month ago | $1.37 | $970.8 | -2.9% |
| 3 months ago | $1.52 | $875 | -12.5% |
| 6 months ago | $1.45 | $917.24 | -8.3% |
| 1 year ago | $1.43 | $930.07 | -7.0% |
| All time (5.0y) ago | $4.15 | $320.48 | -68.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MNOV forecast.
Our base-case forecast reaches $2.70 around 2040.
Implied market cap at $2.70: $132.9M
The multi-year forecast shows a clear bullish trajectory with rising average prices across the horizon. In 2026 the expected average price is $1.40 with 0% ROI, followed by higher levels in subsequent years as the average price grows to $2.19 by 2030 and to $8.36 by 2050, with an estimated 497% ROI in the far horizon. The forecast highlights 2027 (avg $1.51, ROI 7.9%), 2028 (avg $1.57, ROI 11.9%), and 2029 (avg $1.96, ROI 40.1%), indicating accelerating upside as development progresses.
By 2030 the average price is projected at $2.19 with a 56.7% ROI, then rising to $2.28 in 2031 (ROI 62.6%), and $2.55 in 2032 (ROI 82.2%). The path continues with 2033 at $2.52 (ROI 79.9%) and 2034 at $2.61 (ROI 86.5%), culminating in 2035 at $3.12 (ROI 123%). The longer horizon shows substantial upside with 2040 at $4.17 (ROI 197.6%) and 2050 at $8.36 (ROI 497%), underscoring a sustained bullish outlook while acknowledging the inherent uncertainty of such projections.
These are estimates, not guarantees, and actual results will depend on a range of factors including clinical outcomes, regulatory developments, and broader market conditions.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $2.19 with a 56.7% ROI; the range spans from a minimum of $1.71 to a maximum of $3.00, with the sentiment remaining bullish.
Forecasts indicate a bullish long-run trajectory with rising averages and positive ROI across multiple years, reaching $8.36 on average by 2050 (497% ROI). These are estimates and not guarantees, and outcomes depend on various market and development factors.
Yes. The forecasted maximum prices include $6.36 by 2040 and $13.68 by 2050, indicating that passing $5 is within the projected upside range.
The current price is $1.40 and the market capitalization is $68.91M.
The 30-day range is $1.25 to $1.57.
MediciNova, Inc. Community Discussion
0Share your MediciNova, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.